Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?

Background:Malignant glioma is an aggressive tumour commonly associated with a dismal outcome despite optimal surgical and radio-chemotherapy. Since 2005 temozolomide has been established as first-line chemotherapy. We investigate the role of in vivo glioma models in predicting clinical efficacy.Methods:We searched three online databases to systematically identify publications testing temozolomide in animal models of glioma. Median survival and number of animals treated were extracted and quality was assessed using a 12-point scale; random effects meta-analysis was used to estimate efficacy. We analysed the impact of study design and quality and looked for evidence of publication bias.Results:We identified 60 publications using temozolomide in models of glioma, comprising 2443 animals. Temozolomide prolonged survival by a factor of 1.88 (95% CI 1.74–2.03) and reduced tumour volume by 50.4% (41.8–58.9) compared with untreated controls. Study design characteristics accounted for a significant proportion of between-study heterogeneity, and there was evidence of a significant publication bias.Conclusion:These data reflect those from clinical trials in that temozolomide improves survival and reduces tumour volume, even after accounting for publication bias. Experimental in vivo glioma studies of temozolomide differ from those of other glioma therapies in their consistent efficacy and successful translation into clinical medicine.

[1]  S. Fesik,et al.  Hypoxia-Inducible Factor-1 Inhibition in Combination with Temozolomide Treatment Exhibits Robust Antitumor Efficacy In vivo , 2006, Clinical Cancer Research.

[2]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[3]  S P Langdon,et al.  Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. , 1987, Cancer research.

[4]  J. Kovach,et al.  Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms , 2009, Proceedings of the National Academy of Sciences.

[5]  A. Sonabend,et al.  Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo , 2009, British Journal of Cancer.

[6]  N. Bleehen,et al.  Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M R Grever,et al.  Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. , 1994, Cancer research.

[8]  R. Stupp,et al.  Recent developments in the use of chemotherapy in brain tumours. , 2006, European journal of cancer.

[9]  R. Kiss,et al.  Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. , 2008, Neoplasia.

[10]  B. Ross,et al.  Magnetic Resonance Imaging Determination of Tumor Grade and Early Response to Temozolomide in a Genetically Engineered Mouse Model of Glioma , 2007, Clinical Cancer Research.

[11]  C. Kim,et al.  Immunological Factors Relating to the Antitumor Effect of Temozolomide Chemoimmunotherapy in a Murine Glioma Model , 2009, Clinical and Vaccine Immunology.

[12]  M. Berger,et al.  Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. , 2007, Journal of neurosurgery.

[13]  G. Mills,et al.  Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells , 2008, Gene Therapy.

[14]  E. Newlands,et al.  The Charing Cross Hospital experience with temozolomide in patients with gliomas. , 1996, European journal of cancer.

[15]  M. Berger,et al.  p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. , 2008, Cancer research.

[16]  J. Menten,et al.  Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Z. Yue,et al.  Temozolomide/PLGA microparticles: a new protocol for treatment of glioma in rats , 2011, Medical oncology.

[18]  C. James,et al.  Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging , 2011, Journal of magnetic resonance imaging : JMRI.

[19]  A. Sutton,et al.  Comparison of two methods to detect publication bias in meta-analysis. , 2006, JAMA.

[20]  Erin Jackson,et al.  Targeted Inhibition of Cyclic AMP Phosphodiesterase-4 Promotes Brain Tumor Regression , 2008, Clinical Cancer Research.

[21]  R. Simes,et al.  Confronting publication bias: a cohort design for meta-analysis. , 1987, Statistics in medicine.

[22]  W. Weichert,et al.  YB‐1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma , 2011, International journal of cancer.

[23]  M. Berger,et al.  Convection-Enhanced Delivery of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand with Systemic Administration of Temozolomide Prolongs Survival in an Intracranial Glioblastoma Xenograft Model , 2004, Cancer Research.

[24]  Jonathan Lerner,et al.  Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression , 2007, Journal of Neuro-Oncology.

[25]  W. Fellows-Mayle,et al.  Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  C. Verpelli,et al.  Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastoma , 2010, British Journal of Cancer.

[27]  R. Roesler,et al.  Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models , 2009, Journal of Neuro-Oncology.

[28]  G. Donnan,et al.  Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis. , 2007, Brain : a journal of neurology.

[29]  Brett L Carlson,et al.  Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. , 2009, Neuro-oncology.

[30]  R. Blasberg,et al.  Comparison of Corticotropin-Releasing Factor, Dexamethasone, and Temozolomide: Treatment Efficacy and Toxicity in U87 and C6 Intracranial Gliomas , 2011, Clinical Cancer Research.

[31]  Mitchel S. Berger,et al.  Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. , 2011, Neuro-oncology.

[32]  R. McLendon,et al.  Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  Carlijn R Hooijmans,et al.  Enhancing search efficiency by means of a search filter for finding all studies on animal experimentation in PubMed , 2010, Laboratory animals.

[34]  C. Laughton,et al.  Acquired Resistance to Temozolomide in Glioma Cell Lines: Molecular Mechanisms and Potential Translational Applications , 2010, Oncology.

[35]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[36]  Henry Brem,et al.  Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model. , 2011, Biomaterials.

[37]  J. Park,et al.  Enhanced antitumour immunity by combined use of temozolomide and TAT‐survivin pulsed dendritic cells in a murine glioma , 2007, Immunology.

[38]  Tai-Gyu Kim,et al.  Potentiation of antiglioma effect with combined temozolomide and interferon-beta. , 2006, Oncology reports.

[39]  Hyun Seok Song,et al.  Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. , 2006, International journal of oncology.

[40]  L. Stewart,et al.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.

[41]  I. Whittle,et al.  Can experimental models of rodent implantation glioma be improved? A study of pure and mixed glioma cell line tumours , 1998, Journal of Neuro-Oncology.

[42]  E J Freireich,et al.  Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. , 1966, Cancer chemotherapy reports.

[43]  A. Ross,et al.  Cancer esearch apeutics , Targets , and Chemical Biology ecretase Inhibitors Enhance Temozolomide Treatment uman Gliomas by Inhibiting Neurosphere R opulation and Xenograft Recurrence , 2010 .

[44]  D. Khaitan,et al.  Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model , 2009, Cancer biology & therapy.

[45]  C. Leonetti,et al.  Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  S. Yla-Herttuala,et al.  Gene therapy for malignant glioma: current clinical status. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[47]  Rongqin Huang,et al.  Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration. , 2011, Biomaterials.

[48]  E. Alexander,et al.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.

[49]  D. Nam,et al.  Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. , 2006, Oncology reports.

[50]  T. Tominaga,et al.  Enhanced antitumor effect of combined-modality treatment using convection-enhanced delivery of hydrophilic nitrosourea with irradiation or systemic administration of temozolomide in intracranial brain tumor xenografts , 2008, Neurological research.

[51]  M. Macleod,et al.  What is the translational efficacy of chemotherapeutic drug research in neuro-oncology? A systematic review and meta-analysis of the efficacy of BCNU and CCNU in animal models of glioma , 2008, Journal of Neuro-Oncology.

[52]  M. Macleod,et al.  Treatment of intracerebral hemorrhage in animal models: Meta‐analysis , 2011, Annals of neurology.

[53]  David W Howells,et al.  Factors Affecting the Apparent Efficacy and Safety of Tissue Plasminogen Activator in Thrombotic Occlusion Models of Stroke: Systematic Review and Meta-Analysis , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[54]  Z. Yue,et al.  Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[55]  Stefan Michiels,et al.  Meta-analysis when only the median survival times are known: A comparison with individual patient data results , 2005, International Journal of Technology Assessment in Health Care.

[56]  R. Kiss,et al.  Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts. , 2005, Journal of neurosurgery.

[57]  A. Schönthal,et al.  Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin. , 2006, Neurosurgical focus.

[58]  Allison L. Zulli,et al.  The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity , 2007, Molecular Cancer Therapeutics.

[59]  S Duval,et al.  Trim and Fill: A Simple Funnel‐Plot–Based Method of Testing and Adjusting for Publication Bias in Meta‐Analysis , 2000, Biometrics.

[60]  D. Crowther,et al.  Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. , 1995, British Journal of Cancer.

[61]  R. Weichselbaum,et al.  Adenovirally Delivered Tumor Necrosis Factor-α Improves the Antiglioma Efficacy of Concomitant Radiation and Temozolomide Therapy , 2007, Clinical Cancer Research.

[62]  A. Scott,et al.  Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Gianluca Bontempi,et al.  4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs. , 2007, Neoplasia.

[64]  Y. Kondo,et al.  Combined effect of 2-5A-linked antisense against telomerase RNA and conventional therapies on human malignant glioma cells in vitro and in vivo. , 2007, International journal of oncology.

[65]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[66]  C. Kim,et al.  Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model. , 2007, Vaccine.

[67]  Michael D. Prados,et al.  A human brainstem glioma xenograft model enabled for bioluminescence imaging , 2009, Journal of Neuro-Oncology.

[68]  M. Yokoyama,et al.  Convection-enhanced delivery of a synthetic retinoid Am80, loaded into polymeric micelles, prolongs the survival of rats bearing intracranial glioblastoma xenografts. , 2010, The Tohoku journal of experimental medicine.

[69]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[70]  D. Nam,et al.  Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma. , 2010, Oncology reports.

[71]  P. Sandercock,et al.  Comparison of treatment effects between animal experiments and clinical trials: systematic review , 2006, BMJ : British Medical Journal.

[72]  J. Sarkaria,et al.  Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model , 2009, Journal of Neuro-Oncology.

[73]  M. McGraw,et al.  Effect of alternative temozolomide schedules on glioblastoma O6-methylguanine-DNA methyltransferase activity and survival , 2010, British Journal of Cancer.

[74]  A. Schönthal,et al.  Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. , 2011, Cancer letters.

[75]  C. Kennard,et al.  Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. , 1993, European journal of cancer.

[76]  I. Troprès,et al.  Enhancement of survival of 9L gliosarcoma bearing rats following intracerebral delivery of drugs in combination with microbeam radiation therapy. , 2008, European journal of radiology.

[77]  Eric F. Johnson,et al.  ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models , 2007, Clinical Cancer Research.

[78]  R. Weichselbaum,et al.  Transcriptional Targeting of Adenovirally Delivered Tumor Necrosis Factor α by Temozolomide in Experimental Glioblastoma , 2004, Cancer Research.

[79]  G. Velasco,et al.  A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma , 2011, Molecular Cancer Therapeutics.

[80]  C. James,et al.  Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. , 2009, International journal of radiation oncology, biology, physics.

[81]  J. Sarkaria,et al.  Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines , 2009, Molecular Cancer Therapeutics.

[82]  J. Yoshida,et al.  A combination of IFN-β and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation , 2008, Cancer Chemotherapy and Pharmacology.

[83]  H. Brem,et al.  Combination of Intracranial Temozolomide With Intracranial Carmustine Improves Survival When Compared With Either Treatment Alone in a Rodent Glioma Model , 2010, Neurosurgery.